Reusable and disposable insulin pens for the treatment of diabetes: Understanding the global differences in user preference and an evaluation of inpatient insulin pen use

Diabetes Technology and Therapeutics

Volumn 12, Issue SUPPL. 1, 2010, Pages

  Perfetti, Riccardo ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ORAL ANTIDIABETIC AGENT;

COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DISPOSABLE EQUIPMENT; EVIDENCE BASED MEDICINE; GEOGRAPHIC DISTRIBUTION; GLYCEMIC CONTROL; HEALTH CARE ACCESS; HOSPITAL PATIENT; HUMAN; INSULIN PUMP; INTERMETHOD COMPARISON; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT INFORMATION; PATIENT SAFETY; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECYCLING; REVIEW;

EID: 77956143055     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0179     Document Type: Review

References (38)

1. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
2. Diabetes Atlas, 3rd ed. Brussels: International Diabetes Federation, 2009.
3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
4. Centers for Disease Control and Prevention: Treating Diabetes (Insulin and Oral Medication use). http://www.cdc. gov/diabetes/statistics/meduse/fig2. htm (last accessed December 1, 2009).
5. Clarke A, Spollett G: Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv 2007;4:165-174.
6. Davis EM, Bebee A, Crawford L, Destache C: Nurse satisfaction using insulin pens in hospitalized patients. Diabetes Educ 2009;35:799-809.
7. Robertson KE, Glazer NB, Campbell RK: The latest developments in insulin injection devices. Diabetes Educ 2000; 26:135-138, 141-136, 149-152.
8. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL: Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725; discussion 17101711.
9. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl 3):S18-S24.
10. Clarke A, Dain MP: Dose accuracy of a reusable insulin pen using a cartridge system with an integrated plunger mechanism. Expert Opin Drug Deliv 2006;3:677-683.
11. Bode A: Development of the SoloSTAR insulin pen device: design verification and validation. Expert Opin Drug Deliv 2009;6:103-112.
12. Brunton S: Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes mellitus treatment. Am J Med 2008;121(6 Supppl):S35-S41.
13. Kroon L: Overview of insulin delivery pen devices. J Am Pharm Assoc (2003) 2009;(Aug 18):118-131.
14. Pfutzner A: FlexPen for the delivery of insulin: accuracy, injection force and patient preference. Expert Rev Med Devices 2009;6:115-123.
15. Rakel RE: Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. Adv Ther 2009;26:838-846.
16. Spollett G: Insulin devices: addressing barriers to insulin therapy with the ideal pen. Diabetes Educ 2008;34:957-960, 963, 967.
17. IMS Health: IMS Midas (TM) June 2009, Insulin Sales Volume.
18. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R: Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29(Spec No):1294-1305.
19. National Institute for Health and Clinical Excellence: CG87 Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. http://www.nice.org. uk/nicemedia/pdf/CG87NICEGuideline.pdf (accessed September 30, 2009).
20. Institut fur Qualitat Wirtschaftlichkeit im Gesundheitswe-sen: Long acting insulin analogues in the treatment of diabetes mellitus type 2. http://www.iqwig. de/download/A05-03-Executive-summary-Long-acting-insulin- analogues- in-the-treatment-of-diabetes-mellitus-type-2.pdf (accessed September 29, 2009).
21. Peyrot M, Rubin RR: Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus. Curr Med Res Opin 2008;24:2413-2422.
22. Shaghouli AA, Shah BR: The prescription of insulin pen devices versus syringes for older people with diabetes. Diabetes Technol Ther 2009;11:439-442.
23. Lowes L, Davis R: A UK wide survey of insulin initiation in children with type 1 diabetes and nurses' perceptions of associated decision-making. J Clin Nurs 2009;18:1287-1294.
24. McDowell JR, Coates V, Davis R, Brown F, Dromgoole P, Lowes L, Turner EV, Thompson K: Decision-making: initiating insulin therapy for adults with diabetes. J Adv Nurs 2009;65:35-44.
25. Korytkowski M, Bell D, Jacobsen C, Suwannasari R: A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial= syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-2848.
26. Korytkowski M, Niskanen L, Asakura T: FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27(Suppl B):S89-S100.
27. Albano S: Assessment of quality of treatment in insulin-treated patients with diabetes using a pre-filled insulin pen. The ORBITER Study Group. Acta Biomed 2004;75:34-39.
28. Carter J, Beilin J, Morton A, De Luise M: Usability, participant acceptance and safety of a prefilled insulin injection device in a 3-month observational survey in everyday clinical practice in Australia. J Diabetes Sci Technol 2009;3:1425-1438.
29. Carter J, Roberts A: Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia. Curr Med Res Opin 2008;24:2741-2749.
30. Ignaut DA, Schwartz SL, Sarwat S, Murphy HL: Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ 2009;35:789-798.
31. Haak T, Edelman S, Walter C, Lecointre B, Spollett G: Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, Lilly disposable pen, and a prototype pen: an open-label study. Clin Ther 2007;29:650-660.
32. Penfornis A: A user study assessing the performance of a new reusable insulin pen injection device compared with other injection pens available on the market [abstract P-1456]. International Diabetes Federation 20th World Diabetes Congress, Montreal, Quebec, Canada, October 18-22, 2009. http://www. worlddiabetescongress.org/files/docs/abstractbook.pdf (accessed April 6, 2010).
33. Asakura T, Jensen KH: Comparison of intuitiveness, ease of use, and preference in two insulin pens. J Diabetes Sci Technol 2009;3:312-319.
34. Asakura T, Seino H, Jensen KH: Patient acceptance and issues of education of two durable insulin pen devices. Diabetes Technol Ther 2008;10:299-304.
35. Reimer T, Hohberg C, Pfutzner AH, Jorgensen C, Jensen KH, Pfutzner A: Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clin Ther 2008;30:2252-2262.
36. Davis EM, Christensen CM, Nystrom KK, Foral PA, De-stache C: Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm 2008;65:1347-1357.
37. Pellissier G, Migueres B, Tarantola A, Abiteboul D, Lolom I, Bouvet E: Risk of needlestick injuries by injection pens. J Hosp Infect 2006;63:60-64.
38. Food and Drug Administration: Don't share insulin pens between patients. FDA Patient Safety News May 2009; Show #86 (http://www.accessdata. fda. gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=86).